$21.30
▲ +9.2% Today
as of Jul 22, 16:25 ET
Last 30 days
Recent Press Releases & News
XNCR: Rating increased to a HOLD
Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?
Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise
Overview
52-week range
$6.92
$19
100% of range
Avg surprise (last 3)
-40.1%
Avg reaction (last 2)
-2.2%
50% positive
Latest IV / EM
122%
EM ±27.9% · $23 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Wed May 6, 2026 | Mar/2026 | $-1.71 | $-0.65 | -163.1% | -159.1% | +1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.08 | — | — | — | — | financials |
| Wed Aug 6, 2025 | Jun/2025 | $-0.41 | $-0.78 | +47.4% | — | — | earnings |
| Wed May 7, 2025 | Mar/2025 | $-0.66 | $-0.63 | -4.8% | — | -5.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.72 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-1.09 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-1.20 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.40 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.37 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Wed Aug 5, 2026 | Jun/2026 | OTHER | -$0.84 | -$0.41 | -104.9% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | — | $21M | $44M | $33M | — | $18M | $24M |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-78M | — | $-48M | $-33M | $-43M | — | $-55M | $-55M |
| Net income | $-129M | — | $-6M | $-31M | $-48M | — | $-46M | $-67M |
| EPS (diluted) | $-1.71 | — | $-0.08 | $-0.41 | $-0.66 | — | $-0.72 | $-1.09 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $14M | $54M | $28M | $44M | $40M | $41M | $29M | $31M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $483M | $600M | $518M | $513M | $521M | $578M | $590M | $569M |
| Total assets | $737M | $875M | $869M | $879M | $905M | $952M | $1000M | $841M |
| Long-term debt | $82M | $76M | $88M | $95M | $102M | $115M | $128M | $141M |
| Total liabilities | $221M | $240M | $243M | $259M | $265M | $278M | $294M | $292M |
| Total equity | $516M | $636M | $625M | $620M | $640M | $678M | $709M | $550M |